(NASDAQ: AFMD) Affimed Nv's forecast annual revenue growth rate of 33.93% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.39%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Affimed Nv's revenue in 2024 is $8,994,565.On average, 4 Wall Street analysts forecast AFMD's revenue for 2024 to be $76,853,006, with the lowest AFMD revenue forecast at $17,968,406, and the highest AFMD revenue forecast at $137,047,167. On average, 3 Wall Street analysts forecast AFMD's revenue for 2025 to be $59,996,204, with the lowest AFMD revenue forecast at $4,415,964, and the highest AFMD revenue forecast at $137,047,167.
In 2026, AFMD is forecast to generate $389,259,637 in revenue, with the lowest revenue forecast at $49,184,705 and the highest revenue forecast at $981,562,265.